We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Pevion Biotech (vaccines for infectious diseases and cancer) raised CHF35mm ($29.3mm) through its Series A financing led by first-time backer BZ Bank Aktiengesellschaft. Other new investors BB Biotech Ventures and CC Private Equity Partners were joined by returning shareholder Bachem Holding AG. The company will use the proceeds to move its Phase I hepatitis C and breast cancer vaccines into Phase II trials, and to advance its preclinical RSV and Candida vaccines into human studies.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Vaccines
Biotechnology
Large Molecule
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?